Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:IGMS NASDAQ:NXTC NASDAQ:PTLA NASDAQ:ZEAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$6.56-6.0%$6.67$4.09▼$17.24$140.23M0.84281,925 shs189,465 shsIGMSIGM Biosciences$1.36$1.23$0.92▼$22.50$81.29M0.48378,055 shs195,929 shsNXTCNextCure$0.40-15.6%$0.47$0.22▼$1.82$11.08M1.06130,159 shs395,101 shsPTLAPortola Pharmaceuticals$18.03$18.03$5.31▼$31.73$1.42B2.323.17 million shsN/AZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-6.02%-16.86%-17.48%+39.87%-55.07%IGMSIGM Biosciences0.00%+0.37%+7.09%+13.33%-80.60%NXTCNextCure-15.63%-9.61%-35.80%+35.74%-75.00%PTLAPortola Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.9195 of 5 stars3.41.00.04.72.72.50.0IGMSIGM Biosciences4.6217 of 5 stars3.05.00.04.62.73.30.6NXTCNextCure4.568 of 5 stars3.33.00.04.33.91.71.3PTLAPortola PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00174.39% UpsideIGMSIGM Biosciences 1.90Reduce$5.50304.41% UpsideNXTCNextCure 2.67Moderate Buy$3.50786.08% UpsidePTLAPortola Pharmaceuticals 0.00N/AN/AN/AZEALZealand Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTLA, IGMS, NXTC, ENTA, and ZEAL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025NXTCNextCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$67.64M2.07N/AN/A$6.08 per share1.08IGMSIGM Biosciences$2.68M30.34N/AN/A$0.82 per share1.66NXTCNextCureN/AN/AN/AN/A$2.34 per shareN/APTLAPortola Pharmaceuticals$116.64M12.13N/AN/A$1.67 per share10.80ZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)IGMSIGM Biosciences-$195.79M-$3.270.00N/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)NXTCNextCure-$55.65M-$1.760.00N/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)PTLAPortola Pharmaceuticals-$290.66M-$4.06N/AN/AN/A-232.73%-267.86%-54.66%N/AZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/ALatest PTLA, IGMS, NXTC, ENTA, and ZEAL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NXTCNextCure-$0.39N/AN/AN/AN/AN/A8/4/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.10N/AN/AN/A$16.21 millionN/A5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APTLAPortola PharmaceuticalsN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.295.29IGMSIGM BiosciencesN/A5.715.71NXTCNextCureN/A10.2610.26PTLAPortola Pharmaceuticals4.774.874.82ZEALZealand Pharma A/S0.934.794.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%IGMSIGM Biosciences42.79%NXTCNextCure42.65%PTLAPortola Pharmaceuticals98.68%ZEALZealand Pharma A/S1.73%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%IGMSIGM Biosciences57.00%NXTCNextCure17.90%PTLAPortola Pharmaceuticals2.20%ZEALZealand Pharma A/S2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableIGMSIGM Biosciences19059.78 million25.70 millionOptionableNXTCNextCure9028.05 million23.03 millionOptionablePTLAPortola Pharmaceuticals32478.48 millionN/AOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionablePTLA, IGMS, NXTC, ENTA, and ZEAL HeadlinesRecent News About These CompaniesZealand Pharma A/S. (ZLDPF) Institutional Holdings | NasdaqJuly 11 at 8:13 AM | nasdaq.comZealand Pharma A/S. (ZLDPF) Analyst Research | NasdaqJuly 11 at 8:13 AM | nasdaq.comStock Movers: Sainsbury's, Zealand Pharma, Taylor WimpeyJuly 1, 2025 | bloomberg.comZealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for MoreJune 20, 2025 | biospace.comBPositive results for Zealand’s GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | thepharmaletter.comTProthena to lay off majority of staff; Zealand shares obesity drug dataJune 20, 2025 | biopharmadive.comBZealand Pharma’s 46% Stock Slump Makes New Obesity Drug CriticalJune 20, 2025 | bloomberg.comZealand Pharma announces positive topline results from phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | pharmabiz.comPZealand’s GLP-2 candidate shows early weight loss resultsJune 18, 2025 | statnews.comSZealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeksJune 18, 2025 | fiercebiotech.comFZealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 18, 2025 | globenewswire.comZealand Pharma increases its share capital as a result of the exercise of employee warrantsJune 6, 2025 | globenewswire.comZealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndromeJune 2, 2025 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMay 27, 2025 | globenewswire.comEuropean stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10%May 26, 2025 | msn.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comZealand Pharma Appoints Chief Development OfficerMay 20, 2025 | contractpharma.comCZealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development OfficerMay 19, 2025 | globenewswire.comZealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is PriceyMay 16, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsRetail Sales Signal Upside for These 3 Consumer StocksBy Gabriel Osorio-Mazilli | June 22, 2025View Retail Sales Signal Upside for These 3 Consumer StocksSnag These 3 Bargain Tech Stocks Before They PopBy Gabriel Osorio-Mazilli | June 27, 2025View Snag These 3 Bargain Tech Stocks Before They PopPTLA, IGMS, NXTC, ENTA, and ZEAL Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$6.56 -0.42 (-6.02%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.56 0.00 (-0.08%) As of 07/11/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.IGM Biosciences NASDAQ:IGMS$1.36 0.00 (0.00%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.35 -0.01 (-1.03%) As of 07/11/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.NextCure NASDAQ:NXTC$0.40 -0.07 (-15.63%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$0.43 +0.04 (+9.62%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Portola Pharmaceuticals NASDAQ:PTLAPortola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
